Order or find a test

The National Genomic Test Directories specify which genomic tests are commissioned by the NHS in England, to be delivered by Genomic Laboratory Hubs.

Clinical Indication ID & Name

R141

Monogenic diabetes

Test Group

Endocrinology

Test code

R141.1

Test name

N/A

Target genes

Monogenic diabetes (472)

Test scope

n/a

Test method/ technology

WES or Medium Panel

Optimal Family Structure

n/a

Eligibility Criteria

1. Patients with isolated diabetes should be tested if they have:
a. Diabetes diagnosed young (≤35 years in White Europeans and ≤30 years in high prevalence ethnic groups).
AND
b. Unlikely to have Type 1 diabetes because:
They are not on insulin treatment.
OR
They are on insulin treatment with all autoantibodies tested negative (minimum testing of GADA and IA2A) and a random non-fasting C peptide value ≥200pmol/l
AND
c. Have features suggestive of MODY:
An HbA1c at diagnosis of diabetes <7.5% (58mmol/mol), if diagnosed under 18 years of age, OR BMI <30kg/m2 adult (child BMI <95th centile) and a parent with diabetes (if White) or BMI <27kg/m2 (child BMI <95th centile) and a parent with diabetes (if high prevalence type 2 diabetes ethnic group). OR Have a MODY probability score ≥20% if not insulin treated and ≥10% if insulin treated (see https://www.diabetesgenes.org/exeter-diabetes-app/ModyCalculator) 2. Syndromic diabetes: Patients with diabetes AND non-autoimmune extra-pancreatic features • Diabetes diagnosed young AND • Unlikely to have type 1 diabetes (see 1b) or type 2 diabetes. AND • Non-autoimmune extra pancreatic features suggestive of syndromic monogenic diabetes e.g. • Cystic renal disease and/or congenital anomaly of kidney or urinary tract • Bilateral sensorineural deafness • Developmental delay • Developmental defects • Cardiomyopathy • Optic atrophy • Microcephaly 3. Diabetes with severe insulin resistance • Patients have features of severe insulin resistance in the absence of obesity: • Acanthosis nigricans OR • A fasting insulin >150pmol/l if not insulin treated OR if insulin treated an insulin requirement >3U/kg/day
AND
• Diabetes that is unlikely to be type 1 diabetes (see 1.0 above) or type 2
diabetes (BMI<30kg/m2 if white (<95th in children) or BMI <27kg/m2 (<95th in children) if high prevalence type 2 diabetes group).

Test code

R141.2

Test name

N/A

Target genes

GCK;HNF1A;HNF4A;HNF1B

Test scope

n/a

Test method/ technology

MPLA or equivalent

Optimal Family Structure

n/a

Eligibility Criteria

1. Patients with isolated diabetes should be tested if they have:
a. Diabetes diagnosed young (≤35 years in White Europeans and ≤30 years in high prevalence ethnic groups).
AND
b. Unlikely to have Type 1 diabetes because:
They are not on insulin treatment.
OR
They are on insulin treatment with all autoantibodies tested negative (minimum testing of GADA and IA2A) and a random non-fasting C peptide value ≥200pmol/l
AND
c. Have features suggestive of MODY:
An HbA1c at diagnosis of diabetes <7.5% (58mmol/mol), if diagnosed under 18 years of age, OR BMI <30kg/m2 adult (child BMI <95th centile) and a parent with diabetes (if White) or BMI <27kg/m2 (child BMI <95th centile) and a parent with diabetes (if high prevalence type 2 diabetes ethnic group). OR Have a MODY probability score ≥20% if not insulin treated and ≥10% if insulin treated (see https://www.diabetesgenes.org/exeter-diabetes-app/ModyCalculator) 2. Syndromic diabetes: Patients with diabetes AND non-autoimmune extra-pancreatic features • Diabetes diagnosed young AND • Unlikely to have type 1 diabetes (see 1b) or type 2 diabetes. AND • Non-autoimmune extra pancreatic features suggestive of syndromic monogenic diabetes e.g. • Cystic renal disease and/or congenital anomaly of kidney or urinary tract • Bilateral sensorineural deafness • Developmental delay • Developmental defects • Cardiomyopathy • Optic atrophy • Microcephaly 3. Diabetes with severe insulin resistance • Patients have features of severe insulin resistance in the absence of obesity: • Acanthosis nigricans OR • A fasting insulin >150pmol/l if not insulin treated OR if insulin treated an insulin requirement >3U/kg/day
AND
• Diabetes that is unlikely to be type 1 diabetes (see 1.0 above) or type 2
diabetes (BMI<30kg/m2 if white (<95th in children) or BMI <27kg/m2 (<95th in children) if high prevalence type 2 diabetes group).

Commissioning group

Specialised

Overlapping idications

• R158 Lipodystrophy – childhood onset test should be used for congenital severe syndromic forms of lipodystrophy • R142 Glucokinase-related fasting hyperglycaemia test should be used for asymptomatic fasting hyperglycaemia

Address for samples/request forms

Genetics Laboratory
5th Floor Tower Wing
Guy’s Hospital
London
SE1 9RT

Contact with queries

gst-tr.southeastglh@nhs.net

Supporting documents

n/a

Education resources

n/a

Turn around times

All our turnaround times are listed on our specific turn around page https://southeastgenomics.nhs.uk/professionals/service-turn-around-times/

Consent record

See consent guidance in test request form

Sample requirements

Samples may be rejected for the following reasons: 1.Samples and request form do not show at least three identical patient identifiers 2.The sample is in the incorrect collection media 3.The request form is not sufficiently completed 4.The sample is not of sufficient volume 5.The sample is too old